Novel, Next-Generation HIV-1 Maturation Inhibitor GSK3640254 Demonstrates Dose-Dependent Antiviral Response in Treatment-Naive Patients With HIV Infection

Source: 2021 Conference on Retroviruses and Opportunistic Infections*
Download Slideset
March 6-10, 2021; Virtual
Phase IIa study demonstrates that novel maturation inhibitor exhibits dose-response antiviral activity, in vivo concentrations above clinical efficacy targets, and good tolerability.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Silvia Petretti on individualizing antiretroviral therapy according to patient factors from Clinical Care Options

person default Silvia Petretti Released: October 22, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue